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Highlights 
• Limited relationship between certain clinical tests and biomechanical measures of 
stability. 
• Slower walkers had better stability, a potential compensatory mechanism to improve 
stability. 
• ABC scale preferred over PD Gait and fall’s questionnaire in time limited environments. 
• Previous fallers had poorer head and trunk stability. 
• There is a need for more objective clinical measures of postural stability. 
 
Abstract 
This cross-sectional study aimed to investigate the relationship between 
accelerometer-derived measures of movement rhythmicity and clinical measures of mobility, 
balance confidence and gait difficulty in people with Parkinson’s disease (PD). Twenty-nine 
independently-living PD patients (Hoehn & Yahr stages 1-3) with no history of significant 
injury or orthopaedic/deep brain stimulation surgery were recruited from a database of 
patients who had expressed an interest to participate in research. Participants completed 
clinical assessments of mobility, postural stability, balance confidence and symptom severity, 
while head and trunk rhythmicity was evaluated during gait using accelerometers. Following 
data collection, patients were stratified based on disease stage into either a Mild (Hoehn & 
Yahr Stage 1) or Moderate (Hoehn & Yahr Stages 2 to 3) PD group. The results highlighted 
that the Moderate PD group had poorer quality of life, reduced balance confidence and 
increased gait and falls difficulty. Furthermore, for these patients, gait disability and the 
number of previous falls were both negatively correlated with multiple components of head 
and trunk rhythmicity. For the Mild PD group, six-meter walk time was positively correlated 
with ML head rhythmicity and linear regression highlighted a significant predictive 
relationship between these outcomes. For the Mild and Moderate PD groups, balance 
confidence respectively predicted anterior-posterior trunk rhythmicity and vertical head 
rhythmicity. While these findings demonstrate that falls history and the Gait and Falls 
questionnaire provide moderate insight into head and trunk rhythmicity in Moderate PD 
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patients, objective and clinically-feasible measures of postural instability would assist with 
the management of these symptoms.  
 
Abbreviations: 
ABC = Activities-Specific Balance Confidence Scale 
ACE = Addenbrooke’s Cognitive Examination 
PD = Parkinson’s disease 
TUG = Timed up and Go test 
UPDRS = Unified Parkinson’s disease Rating Scale 
 
Keywords:   Parkinson’s disease; Motor Control; Falls; Quality of Life, Postural 
Stability 
 
Introduction 
Postural instability is one of the most disabling symptoms of Parkinson’s disease (PD) 
and  significantly increases the risk of falling[1]. The costs of falls and falls-related injuries 
are not well established for many countries[2], but Australian estimates indicate that 
approximately AUD$27.5 million was spent on injuries associated with falls and falls-related 
injuries in 2010[3]. Given the significant physical and financial burden associated with falls 
in PD, a clear need exists to develop an improved capacity to assess symptoms of postural 
instability to assist with their early identification and treatment. For people with PD, 
symptoms of postural instability are often accompanied by a decline in the patient’s 
mobility[4]. Traditionally, clinical tests like the Timed up and Go (TUG)[5] and 10-meter[4] 
(or 6-meter[6]) walk tests have been used to assess changes in mobility for a range of 
healthy[7] and pathological[4] populations. Given the ease with which they can be 
administered and their widespread use in hospitals and other clinical settings, it is not 
surprising that such tests are often used to assess the efficacy of exercise interventions aimed 
at improving mobility and/or preventing falls in people with PD[8]. However, despite their 
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widespread use for the assessment of people with PD[9], research suggests that some of these 
clinical tests are not always able to identify differences in mobility between people with PD 
and age-matched controls[10, 11].  Therefore, while the TUG and 6-meter walk tests are 
widely acceptable as clinical tests of mobility, there seems to be a need for further 
investigations to determine whether such clinical tests have the capacity to identify changes 
in postural stability in people with PD. 
 
The improved availability and affordability of wearable sensors has now made it 
feasible to develop and/or enhance clinical assessments to incorporate more objective 
measures of walking stability. For example, research has shown that by placing a wearable 
sensor on a patient’s body during the performance of the TUG test, the objectivity of the 
assessment can be significantly improved[11]. Specifically, research utilising this adaptation 
of the TUG test has reported differences in the amplitude, rhythmicity and smoothness of 
segmental motion (as measured using RMS accelerations, harmonic ratios and jerk, 
respectively) for people with PD compared with age-matched controls[12]. Of the numerous 
accelerometer-based outcomes reported in the literature, the harmonic ratio (HR) is the most 
commonly reported for people with PD[13] and provides a measure of gait rhythmicity by 
assessing the ratio of in-phase accelerations to out-of-phase accelerations within a given gait 
cycle[14].  Additionally, the HR has been shown to have the capacity to discriminate PD 
patients with a history of falling from patients who have not previously fallen[15].  Despite 
its frequent use in the research setting, more traditional tests of mobility continue to prevail in 
daily clinical practices. As such, this study aimed to determine whether the results of 
common clinical tests of mobility, balance confidence and gait difficulty correlate with 
laboratory-based measures of postural stability to determine whether these assessments offer 
insight into deficits in postural stability for people with PD.  It was hypothesised that clinical 
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measures of mobility, gait difficulty, postural stability and balance confidence would not be 
related to movement rhythmicity and, therefore, offer limited insight into dynamic postural 
stability. 
 
Methods 
Participants 
Thirty participants diagnosed with idiopathic PD, based on the UK Brain Bank Criteria were 
recruited. Patients with a history of two or more near-misses and/or at least one fall in the 
previous 12 months were contacted via a pre-existing database of people with PD who had 
expressed an interest to participate in research. Prospective participants received an 
information letter outlining the study’s details and inviting them to contact a member of the 
research team if they were interested in volunteering.  Participants were excluded if they 
were; i) unable to stand and walk independently; ii) significantly visually (Bailey-Lovie high 
contrast visual acuity > 0.30 logMAR) or cognitively impaired (Addenbrooke’s cognition 
examination score <82); iii) known to have uncontrolled hypertension; iv) taking 
psychotropic medications; v) significantly limited by osteoporosis; vi) a recipient of 
orthopaedic surgery within the previous year; vii) suffering serious neck, shoulder or back 
injuries (including spinal fusions); or viii) a recipient of deep brain stimulation surgery to 
manage their symptoms. Experimental procedures were approved by the University’s Human 
Research Ethics Committee and volunteers provided written informed consent. An a-priori 
sample size calculation based on a p-value of 0.05, a power of 80% and a large effect size 
(ρ=0.6) indicated that at least 13 participants were required per group to examine the 
relationships between the clinical tests and harmonic ratios. 
 
Experimental Protocol 
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Individuals attended a single testing session during which a battery of tests was performed 
including clinical assessments of; i) cognition (Addenbrooke’s Cognitive Examination 
(ACE));  ii) visual acuity (Bailey-Lovie high contrast visual acuity); iii) symptom severity 
(Unified Parkinson’s Disease Rating Scale (UPDRS), the modified Hoehn & Yahr (H&Y) 
scale, the Schwab & England Activities of Daily Living Scale, the PD Gait and Falls 
questionnaire and the Freezing of Gait (FOG) questionnaire); iv) balance confidence 
(Activity-specific Balance Confidence (ABC) scale); and v) quality of life (39-item 
Parkinson’s Disease Questionnaire (PDQ-39)). A measure of postural instability and gait 
disability (PIGD) was also calculated for each participant by summing items 27-30 of the 
UPDRS motor sub-section[16]. The ACE was used to assess cognition, as it incorporates the 
Mini Mental State Examination and has high sensitivity and specificity for detecting 
dementia (cut-off score of <82 gives 82% sensitivity and 100% specificity). These 
assessments were selected due to their established reliability, validity[17, 18] and previous 
use in assessing individuals with PD[19]. In addition to the clinical assessments, participants 
were also asked to report any falls and/or near misses experienced in the previous year. For 
this study, a fall was defined as “any coming to the ground or other lower level not as the 
result of a major intrinsic event or overwhelming hazard[20]”. A near miss was defined as  
“an event on which an individual felt that they were going to fall but did not actually do 
so[20]”.  
 
Following the questionnaire-based assessments, participants completed five barefoot 
trials of the TUG test. Participants were seated in a 42cm high chair with their feet flat on the 
floor, their back flat against the backrest and their arms resting on the armrests, which were 
situated 20 cm above the seat. Upon the word ‘GO,’ participants were required to stand from 
the chair and walk at a brisk, but comfortable pace to a line on the floor three meters away, 
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turn around and return to the chair to sit down.  The time taken to complete the test was 
recorded using a stopwatch. Following the TUG test, participants completed 6 barefoot 
walking trials at a comfortable pace along a 10-meter firm walkway. In accordance with the 
established procedures of the 6-meter walk test (6MWT), walking speed was assessed over 
the middle 6-meter distance using a dual beamed timing gait system (SWIFT Performance 
Equipment, Alstonville, Australia) that was positioned at hip height. 
 
Gait rhythmicity was assessed during the 6MWT using two microelectromechanical 
(MEMS) three-dimensional accelerometers (1500 Hz; Noraxon Inc., Scottsdale, AZ) to 
provide insight into the patients’ dynamic postural control. Each accelerometer was statically-
calibrated prior to attachment by aligning each of its sensing axes perpendicular to a 
horizontal surface to establish the exact value of gravitational acceleration (i.e. 1 gravitational 
unit or 1g)[14]. Following static calibration, one accelerometer was firmly attached to a sport 
headband and positioned over the occipital protuberance and the second accelerometer was 
firmly attached using double-sided tape to the skin overlying the spinous process of the 10th 
thoracic vertebra (T10) and reinforced with Micropore. During the 6MWT trials, 3D head 
and trunk accelerations were wirelessly telemetered to a Telemyo DTS unit, which was 
connected to a laptop computer running the MyoResearch XP (v1.08) software. 
 
Data Analysis 
Raw accelerations were transformed to represent a horizontal-vertical orthogonal 
coordinate system[14]. Transformation was necessary, as accelerometers measured data 
relative to a local (or internal) rather than global coordinate system. As such, positioning 
sensors on body segments often results in two or more of the sensing axes being influenced 
by gravitational accelerations, which can make it difficult to identify the proportion of the 
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signal attributable to movement-related accelerations[14]. After data transformation, 
accelerations were filtered using a bi-directional fourth-order low-pass Butterworth filter with 
a cut-off frequency of 30 Hz[21]. Given 99% of accelerations during walking occur at or 
below 15 Hz[22], the cut-off frequency of 30 Hz was sufficient to ensure higher frequencies, 
unrelated to movement, were attenuated without influencing the gait-related accelerations. 
Filtered and transformed accelerations for the anteroposterior (AP), mediolateral (ML) and 
vertical (VT) axes were then used to derive the HRs for head and trunk segments, separately.  
To calculate the harmonic ratios, the time-series data were divided into individual gait cycles 
by identifying the positive peaks in the VT trunk accelerations, which coincided with heel 
contact. Using a custom Matlab program (version R2015), AP, ML and VT harmonic ratios 
were calculated for four consecutive gait cycles identified in the central portion of each 
6MWT trial. As the HR provides a ratio of the in-phase to out-of-phase accelerations during 
gait, larger values are considered to represent more regular movement patterns, while lower 
values represent less regular movements[14]. 
 
Statistical Analysis 
Following processing, data were sub-divided based on each patient’s H&Y stage 
score. Patients who had mild symptoms affecting one side of the body only (H&Y Stage 1) 
were combined to form a Mild PD group, while data for patients presenting with Mild (H&Y 
Stage 2) to Moderate (H&Y Stage 3) bilateral symptoms were combined to form a Moderate 
PD group. To assess for any significant differences between the groups with respect to the 
continuous demographic variables and clinical assessments, a one-way analysis of variance 
(ANOVA) was used, while the Chi-square tests were used to identify any differences in the 
frequency of categorical data.  If the assumptions of normality (Shapiro-Wilks test) and/or 
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homogeneity of variance (Levene’s test) were violated, the equivalent non-parametric Mann-
Whitney was used for the continuous variables[23]. 
   
Bivariate correlations were used to establish the relationship between clinical tests of 
mobility and stability and laboratory-based measures of dynamic postural control. To 
determine the appropriateness of the parametric Pearson’s correlation coefficient, the 
normality of the continuous measures was assessed using the Shapiro-Wilk test and where a 
p-value less than 0.05 was returned, the non-parametric Spearman’s Rho test was used.  
Linear regression analyses examined whether clinical measures of mobility, postural stability, 
balance confidence and gait difficulty were capable of explaining a significant proportion of 
the variance in head and trunk rhythmicity during walking.  Statistical analyses were 
performed in SPSS version 22 (New York, USA) with significance set at p<0.05. 
 
Results 
Of the thirty participants recruited, one was excluded prior to completing the assessments due 
to deficits in cognitive function (i.e. ACE total score <82). Based on the neurological 
assessment, the remaining 29 patients had mild to moderate symptoms of PD, were 
independently living and most (90%) were taking anti-parkinsonian medication. Patients 
comprising the Moderate PD group were shown to have more severe motor symptoms 
(p=0.004) and reported poorer balance confidence (p<0.001), poorer quality of life (p=0.001), 
a greater incidence of freezing of gait (p=0.040) and increased postural instability and gait 
difficulty (p=0.002) compared with the Mild PD group (Table 1).      
 
 
Correlation Analyses  
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Tests of normality indicated that a number of the continuous outcome measures were not 
normally distributed, hence the non-parametric Spearman’s Rho test was used to assess the 
relationships between the clinical tests and the accelerometer-based measures of walking 
rhythmicity (Table 2).  For the whole PD sample, previous falls were shown to be positively 
correlated with the gait and falls questionnaire (ρ=0.508, p=0.005) and negatively correlated 
with the 6-meter walk time (ρ=-0.466, p=0.011) and all harmonic ratios for the head (ρ=-
0.448 to -0.513, p≤0.02) and trunk (ρ=-0.437 to -0.623, p≤0.02). The sub-group analyses 
indicated that these relationships were further strengthened for the Moderate PD patients, 
when patients with milder symptoms were considered separately. Specifically, the bivariate 
correlations revealed that previous falls were moderately positively correlated with gait and 
falls difficulty (ρ=0.600, p=0.014) and moderately negatively correlated with 6-meter walk 
time (ρ=-0.531, p=0.034) and all head (ρ=-0.537 to -0.693, p≤0.05) and most trunk (ρ=-0.595 
to -0.766, p≤0.015) HRs.  In contrast, the number of previous falls was moderately positively 
correlated with balance confidence (ρ=0.555, p=0.049) and moderately negatively correlated 
with AP trunk rhythmicity (ρ=-0.611, p=0.027) for the Mild PD patients.  
 
Analysis of the two mobility assessments demonstrated that the 6-meter walk time negatively 
correlated with gait speed (ρ=-1.000, p<0.001) and positively correlated with TUG total time 
(ρ=0.519, p=0.004) and mediolateral head HR (ρ=0.416, p=0.025). The sub-group analyses 
showed that the 6-meter walk time was moderately positively correlated with TUG total time 
(ρ=0.624, p=0.010) for the Moderate PD group, while ML head rhythmicity was moderately 
positively correlated with the 6-meter walk time (ρ=0.573, p=0.041) for the Mild PD group. 
For the whole PD cohort, TUG total time was negatively correlated with gait speed (ρ=-
0.519, p=0.004) and balance confidence (ρ=-0.565, p=0.001), but the sub-group analyses 
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revealed that these relationships only remained significant for the Moderate PD group (gait 
speed: ρ=-0.624, p=0.010; ABC: ρ=-0.708, p=0.002).   
 
Similar to clinical tests of mobility, the retropulsion test was negatively correlated with 
balance confidence (ρ=-0.595, p=0.001) and positively associated with the Gait and Falls 
questionnaire (ρ=0.434, p=0.019). Additionally, the Gait and Falls questionnaire was 
moderately negatively correlated with balance confidence (ρ=-0.555, p=0.002) and AP trunk 
rhythmicity (ρ=-0.425, p=0.022). The sub-group analyses indicated that the retropulsion test 
was moderately negatively correlated with balance confidence (ρ=-0.652, p=0.006) and AP 
head rhythmicity (ρ=-0.499, p=0.049) for the Moderate PD group.  Furthermore, for the 
Moderate PD group, the gait and falls questionnaire was moderately negatively correlated 
with balance confidence (ρ=-0.521, p=0.038) and most head (ρ=-0.526 to -0.538, p<0.05) and 
all trunk (ρ=-0.510 to -0.642, p<0.05) HRs.  No other relationships were observed between 
the questionnaires and the objective measures of walking stability (Table 2). 
 
 
Regression Analysis 
 The linear regression analyses performed for the entire PD cohort indicated that, of all 
of the clinical assessments conducted, the 6MWT and ABC scale were the only tests that 
were able to predict any component of head or trunk rhythmicity. Specifically, the 6MWT 
predicted ML head HRs (p=0.041) and the ABC scale predicted VT head HRs (p=0.032). 
Similar results were returned for the regression analyses conducted for the two sub-groups, 
with the 6MWT predicted ML head HRs (p=0.036) for the Mild PD group and the ABC scale 
predicted AP trunk HRs (p=0.012) and VT head HRs (p=0.047) for the Mild and Moderate 
PD groups, respectively (Table 3). 
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Discussion 
The purpose of this study was to examine whether common clinical tests of mobility, 
postural stability, balance confidence and gait difficulty were capable of providing insight 
into walking stability in people with PD.  The results indicated that individuals with moderate 
disease severity reported experiencing poorer balance confidence, greater postural instability 
and gait difficulty and poorer quality of life than patients with milder symptoms.  
Interestingly, however, the Moderate and Mild PD groups had similar results for the 
clinically-administered assessments, including the retropulsion test, TUG and 6MWT. 
Similar findings were evident for the correlation analyses, which indicated that while the 
outcomes of the clinically-administered tests were not correlated with the measures of head 
and trunk rhythmicity, those patients in the Moderate PD group who reported a greater 
number of previous falls and/or greater difficulties with gait and falls also had poorer head 
and trunk rhythmicity. These findings were similar to previous research that has shown that 
PD fallers with moderate symptoms had poorer head and pelvis rhythmicity during gait than 
patients with milder symptoms who had not previously fallen[15]. Collectively, these 
findings suggest that clinical measures of balance, mobility, gait difficulty and balance 
confidence may not provide insight into the walking rhythmicity of individuals with milder 
symptoms.  However, for patients who have more advanced symptoms, it seems that the 
assessments that rely more on a patient’s self-reported difficulties may provide better insight 
into the gait rhythmicity of these patients.   These findings would appear to have important 
clinical implications and suggest that objectively evaluating a patient’s mobility without 
considering their perceived difficulties may inadvertently result in important information 
regarding falls risk being overlooked. Nevertheless, it is widely recognised that self-report 
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assessments can be limited by patients over- or under-reporting their difficulties, hence more 
objective tests would greatly benefit the clinical assessment of postural stability in people 
with PD.  
 
The retropulsion test is one of the most commonly used clinical assessment of 
postural stability for people with PD and is incorporated into the motor sub-section of the 
UPDRS[24]. Despite its widespread use and its apparent capacity to assess a patient’s 
stability under static conditions, previous research has highlighted its inability to discriminate 
PD fallers from non-fallers[25] or single fallers from recurrent fallers in cohorts with and 
without PD[26]. While our findings largely agreed with these studies, it is important to 
highlight that the retropulsion test was significantly correlated with AP head rhythmicity in 
individuals with moderate symptom severity.  Given that the retropulsion test examines a 
patient’s postural response to a firm backward pull on their shoulders, it is perhaps not 
surprising that those who scored more poorly on the retropulsion test also demonstrated 
poorer AP head control during gait (i.e. lower AP head HRs).  The poor relationship between 
the retropulsion test and the continuous measures of head and trunk rhythmicity may be 
explained, at least in part, by a number of factors. First, the retropulsion test is somewhat 
limited by its use of a Likert scale that ranges from zero (normal response) to four (unable to 
stand without assistance).  Specifically, for a patient’s score to change from a zero to a one 
for the retropulsion test, they must demonstrate a retropulsive gait pattern and recover 
without assistance. Given the marked heterogeneity of PD symptoms, it is very likely that 
some patients will develop difficulties that affect their gait and balance, but do not manifest 
in the form of a retropulsive gait pattern during the retropulsion test. A second factor that 
may influence the applicability of the retropulsion test to dynamic situations could be the fact 
that it assesses postural stability during quiet stance rather than under dynamic conditions. 
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Given that only 32% of falls occur during standing[27], it is possible that the retropulsion test 
may be limited in its capacity to explain the factors contributing to the 66% of falls that occur 
during ambulation and transfer events[27]. 
 
Another interesting finding of this study was that the number of previous falls 
experienced by patients in the Mild PD group was significantly positively correlated with 
balance confidence, suggesting that individuals who fell more had greater balance 
confidence. This finding is in contrast with a growing body of literature that supports the use 
of the ABC scale for assessing balance confidence in people with PD and for identifying 
patients who are at an increased risk of future recurrent falls[28, 29].  While the 
uncharacteristically high balance confidence reported for individuals in the Mild PD group 
may have been influenced by their higher level of motor functioning (i.e. lower UPDRS 
scores) and the improved quality of life reported for these patients, it remains unclear what 
attributes of the disease most influence one’s perceived risk of falling.  As such, there is a 
need for future research to examine how self-reported balance confidence changes with 
disease progression and to establish what symptoms are most likely to influence one’s fear of 
falling. 
 
As with any study, our results should be considered in the context of a couple of 
limitations. First, our sample size, particularly once stratified based on disease severity, may 
be considered quite small from a statistical perspective. While the two groups were at least 
the size of the minimum group size determined in our a-priori sample size calculation, further 
research involving larger cohorts would be warranted. Second, the patients involved in this 
study were typically of mild to moderate disease severity (Hoehn & Yahr stages 1 to 3), 
hence the transferability of our findings may be limited to similar patient cohorts.   
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Conclusion 
Although existing tests of mobility, postural stability, balance confidence and gait 
difficulty provide little insight into movement rhythmicity in individuals with mild symptom 
severity, this study suggests that falls history and the Gait and Falls questionnaire may 
provide some insight into head and trunk rhythmicity in individuals with moderate symptom 
severity.  Nevertheless, given that these measures rely on accurate patient recall, the 
development and implementation of objective and clinically-feasible measures of postural 
instability and gait disability would help to improve the management of these symptoms in 
people with PD. 
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Table 1. Demographic information and results for the assessments of mobility, balance confidence, quality of life and symptom severity for the 
Mild and Moderate PD groups. 
 
All PD 
(n = 29) 
Mild PD 
(n = 13) 
Moderate PD  
(n = 16) 
Test p-value 
Demographics      
Male 21 (72.4%) 8 (61.5%) 13 (81.3%) 3 0.238 
Age (years) 64.7 ± 6.4 62.8 ± 7.1 66.3 ± 5.4 1 0.147 
Height (cm) 171.7 ± 8.0 170.6 ± 8.9 172.6 ± 7.3 1 0.504 
Mass (kg) 80.4 ± 20.1 78.8 ± 20.2 81.7 ± 20.7 1 0.709 
Body Mass Index (kg/m2) 27.0 ± 5.3 26.8 ± 5.1 27.2 ± 5.6 1 0.853 
Cognition and Vision      
Addenbrooke’s Cognitive Exam 91.7 ± 6.1 92.5 ± 5.2 91.1 ± 6.8 1 0.527 
High Contrast Visual Acuity (LogMAR) 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1 2 0.475 
Balance Confidence and Quality of Life      
Previous Fallers 23 (79.3%) 11 (84.6%) 12 (75.0%) 3 0.525 
Previous Falls 1.4 ± 2.0 1.2 ± 1.5 1.6 ± 2.4 2 0.846 
Activities-specific Balance Confidence (%) 77.8 ± 24.8 93.2 ± 6.6 65.4 ± 27.4 2 <0.001 
39-Item Parkinson’s Disease Questionnaire 23.5 ± 15.3 14.9 ± 6.9 30.4 ± 16.9 2 0.001 
Mobility      
Timed Up and Go Total Time (s) 9.4 ± 1.5 9.0 ± 1.2 9.8 ± 1.7 1 0.202 
6-Meter Walk Test (s) 4.7 ± 0.6 4.8 ± 0.5 4.7 ± 0.7 1 0.647 
Neurological Examination      
Disease Duration (years) 6.7 ± 5.3 4.9 ± 1.1 8.1 ± 6.8 2 0.288 
Unified Parkinson’s Disease Rating Scale (Part III) 14.4 ± 11.5 9.1 ± 2.3 18.8 ± 14.1 2 0.004 
Hoehn & Yahr Stage Score  1.7 ± 0.7 1.0 ± 0.0 2.2 ± 0.4 2 <0.001 
Schwab & England Activities of Daily Living Scale 86.6 ± 7.5 90.0 ± 4.1 83.8 ± 8.5 2 0.056 
Freezing of Gait Score 4.9 ± 5.2 2.7 ± 2.9 6.7 ± 6.0 2 0.040 
Postural Instability and Gait Disorder Score 1.9 ± 1.6 0.8 ± 1.0 2.7 ± 1.6 2 0.002 
Retropulsion Test 0.5 ± 0.7 0.2 ± 0.4 0.8 ± 0.9 2 0.083 
Levodopa (mg/day) 618.3 ± 432.1 545.2 ± 350.7 677.8 ± 491.7 1 0.421 
Dopamine Agonists 6 (20.7%) 2 (15.4%) 4 (25.0%) 3 0.468 
Catechol-O-Methyl Transferase Inhibitors 9 (31.0%) 4 (30.8%) 5 (31.3%) 3 0.885 
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Monoamine Oxidase Inhibitors 10 (34.5%) 3 (23.1%) 7 (43.8%) 3 0.194 
Benzodiazepine  1 (3.4%) 1 (7.7%) 0 (0.0%) 3 0.274 
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Table 2: Spearman’s Rho correlations between the clinical balance and mobility tests and the objective measures of walking rhythmicity for the entire PD cohort 
and the Mild and Moderate PD sub-groups. 
   All PD Mild PD Moderate PD 
   
Spearman’s 
Rho 
p-value 
Spearman’s 
Rho 
p-value 
Spearman’s 
Rho 
p-value 
Retrospective Falls 6-Meter Walk Time  -0.466 0.011* -0.344 0.250 -0.531 0.034* 
 Timed Up and Go Total Time  -0.169 0.381 -0.194 0.526 -0.193 0.474 
 Retropulsion Test  0.008 0.965 0.077 0.802 0.055 0.839 
 Gait & Falls Questionnaire  0.508 0.005* 0.274 0.365 0.600 0.014* 
 Activities-Specific Balance Confidence Scale  0.039 0.839 0.555 0.049* 0.038 0.889 
 Harmonic Ratio (Head) AP -0.465 0.011* -0.521 0.068 -0.537 0.032* 
  ML -0.448 0.015* -0.320 0.286 -0.579 0.019* 
  VT -0.513 0.004* -0.436 0.137 -0.693 0.003* 
 Harmonic Ratio (Trunk) AP -0.524 0.004* -0.611 0.027* -0.430 0.097 
  ML -0.437 0.018* -0.272 0.369 -0.595 0.015* 
  VT -0.623 <0.001* -0.436 0.137 -0.766 0.001* 
6-Meter Walk Time Gait Speed  -1.000 <0.001* -1.000 <0.001* -1.000 <0.001* 
 Timed up and Go Total Time  0.519 0.004* 0.287 0.343 0.624 0.010* 
 Retropulsion Test  0.082 0.672 -0.286 0.344 0.268 0.315 
 Gait & Falls Questionnaire  -0.134 0.487 -0.034 0.913 -0.158 0.560 
 Activities-Specific Balance Confidence Scale  -0.197 0.307 -0.228 0.453 -0.474 0.064 
 Harmonic Ratio (Head) AP 0.163 0.397 0.571 0.571 0.174 0.520 
  ML 0.416 0.025* 0.573 0.041* 0.365 0.165 
  VT 0.035 0.857 0.174 0.571 -0.026 0.922 
 Harmonic Ratio (Trunk) AP 0.020 0.918 0.025 0.936 0.038 0.888 
  ML 0.313 0.099 0.446 0.126 0.194 0.471 
  VT 0.003 0.988 0.209 0.492 -0.091 0.737 
Timed Up and Go Total Gait Speed  -0.519 0.004* -0.287 0.343 -0.624 0.010* 
 Retropulsion Test  0.320 0.091 -0.171 0.577 0.413 0.112 
 Gait & Falls Questionnaire  0.352 0.061 0.539 0.058 0.257 0.336 
 Activities-Specific Balance Confidence Scale  -0.565 0.001* -0.472 0.104 -0.708 0.002* 
22 
 
 Harmonic Ratio (Head) AP 0.358 0.057 0.440 0.133 0.035 0.897 
  ML 0.326 0.084 0.225 0.459 0.169 0.531 
  VT 0.297 0.118 0.324 0.280 0.107 0.692 
 Harmonic Ratio (Trunk) AP 0.053 0.783 0.280 0.354 -0.187 0.488 
  ML 0.278 0.145 0.473 0.103 -0.075 0.782 
  VT 0.110 0.570 0.110 0.721 -0.097 0.720 
Retropulsion Test Gait Speed  -0.082 0.672 0.286 0.344 -0.268 0.315 
 Gait & Falls Questionnaire  0.434 0.019* 0.087 0.777 0.349 0.185 
 Activities-Specific Balance Confidence Scale  -0.595 0.001* -0.143 0.641 -0.652 0.006* 
 Harmonic Ratio (Head) AP -0.297 0.118 -0.285 0.345 -0.499 0.049* 
  ML -0.143 0.458 -0.513 0.073 -0.422 0.104 
  VT 0.119 0.540 -0.057 0.853 -0.051 0.851 
 Harmonic Ratio (Trunk) AP -0.102 0.597 0.342 0.253 -0.275 0.303 
  ML 0.089 0.645 0.228 0.454 -0.173 0.523 
  VT 0.116 0.550 0.114 0.711 -0.064 0.814 
Gait & Falls Questionnaire Gait Speed  0.134 0.487 0.034 0.913 0.158 0.560 
 Activities-Specific Balance Confidence Scale  -0.555 0.002* 0.007 0.982 -0.521 0.038* 
 Harmonic Ratio (Head) AP -0.176 0.360 0.067 0.827 -0.526 0.036* 
  ML -0.107 0.579 0.079 0.799 -0.538 0.032* 
  VT -0.042 0.828 0.163 0.595 -0.496 0.051 
 Harmonic Ratio (Trunk) AP -0.425 0.022* -0.115 0.708 -0.642 0.007* 
  ML -0.201 0.296 0.129 0.674 -0.510 0.044* 
  VT -0.267 0.162 0.022 0.942 -0.638 0.008* 
Activities-Specific Balance Gait Speed  0.197 0.307 0.228 0.453 0.474 0.064 
Confidence Scale Harmonic Ratio (Head) AP -0.119 0.540 0.025 0.936 -0.032 0.905 
  ML -0.256 0.181 0.014 0.964 0.159 0.557 
  VT -0.322 0.088 0.061 0.844 -0.291 0.274 
 Harmonic Ratio (Trunk) AP -0.014 0.944 -0.505 0.078 0.126 0.641 
  ML -0.209 0.277 -0.356 0.233 -0.153 0.572 
  VT -0.158 0.414 0.168 0.583 -0.112 0.680 
AP = Anteroposterior, ML = Mediolateral, VT = Vertical, * = Significant correlation  
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Table 3: Results of the linear regression analyses conducted between the clinical balance and mobility tests and the objective measures of walking rhythmicity for 
the entire PD cohort and the Mild and Moderate PD sub-groups. 
   All PD Mild PD Moderate PD 
   
Unstandardised 
beta (B) 
Standardised 
Beta (β) 
p-value 
Unstandardised 
beta (B) 
Standardised 
Beta (β) 
p-value 
Unstandardised 
beta (B) 
Standardised 
Beta (β) 
p-value 
Retrospective Falls           
  AP -0.499 -0.179 0.354 -0.668 -0.316 0.293 -0.491 -0.153 0.572 
 Harmonic Ratio (Head) ML -0.478 -0.164 0.395 -0.301 -0.125 0.683 -0.787 -0.236 0.379 
  VT -0.671 -0.271 0.155 -0.469 -0.287 0.342 -1.074 -0.331 0.211 
  AP -0.755 -0.238 0.214 -0.868 -0.352 0.239 -0.671 -0.191 0.479 
 Harmonic Ratio (Trunk) ML -0.437 -0.135 0.486 -0.218 -0.100 0.746 -0.729 -0.181 0.502 
  VT -0.683 -0.321 0.089 -0.506 -0.319 0.288 -0.934 -0.374 0.154 
6-Meter Walk Time           
  AP 0.121 0.154 0.424 0.148 0.222 0.465 0.142 0.160 0.553 
 Harmonic Ratio (Head) ML 0.348 0.382 0.041* 0.500 0.585 0.036* 0.423 0.398 0.127 
  VT 0.064 0.086 0.657 0.160 0.299 0.322 -0.003 -0.003 0.993 
  AP 0.036 0.183 0.846 0.030 0.040 0.897 0.040 0.037 0.892 
 Harmonic Ratio (Trunk) ML 0.237 0.238 0.214 0.296 0.404 0.171 0.224 0.180 0.504 
  VT 0.005 0.008 0.966 0.177 0.330 0.270 -0.076 -0.110 0.684 
Timed Up and Go Total           
  AP 0.663 0.363 0.053 0.676 0.459 0.115 0.535 0.265 0.321 
 Harmonic Ratio (Head) ML 0.577 0.272 0.153 0.263 0.139 0.651 0.547 0.226 0.400 
  VT 0.516 0.301 0.113 0.255 0.215 0.482 0.664 0.291 0.274 
  AP 0.036 0.016 0.933 0.413 0.246 0.418 -0.256 -0.104 0.701 
 Harmonic Ratio (Trunk) ML 0.713 0.309 0.103 0.817 0.503 0.080 0.423 0.149 0.581 
  VT 0.302 0.214 0.265 0.138 0.116 0.705 0.273 0.174 0.519 
Retropulsion Test           
  AP -0.243 -0.271 0.155 -0.128 -0.267 0.378 -0.491 -0.483 0.058 
 Harmonic Ratio (Head) ML -0.124 -0.199 0.538 -0.259 -0.419 0.154 -0.402 -0.330 0.212 
  VT 0.085 0.101 0.603 0.028 -0.072 0.815 -0.007 -0.006 0.982 
  AP -0.107 -0.098 0.612 0.153 0.280 0.354 -0.308 -0.249 0.352 
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 Harmonic Ratio (Trunk) ML 0.059 0.052 0.790 0.044 0.084 0.785 -0.109 -0.077 0.778 
  VT 0.051 0.074 0.703 0.020 0.053 0.864 -0.069 -0.087 0.748 
Gait & Falls Questionnaire           
  AP -3.309 -0.207 0.282 0.238 0.052 0.866 -8.161 -0.449 0.081 
 Harmonic Ratio (Head) ML -2.575 -0.154 0.425 0.765 0.147 0.631 -8.745 -0.465 0.070 
  VT -0.774 -0.055 0.779 0.557 0.158 0.607 -5.408 -0.295 0.268 
  AP -6.204 -0.341 0.071 -0.096 -0.018 0.954 -9.312 -0.469 0.067 
 Harmonic Ratio (Trunk) ML -3.315 -0.178 0.355 0.180 0.038 0.902 -8.699 -0.383 0.143 
  VT -2.140 -0.175 0.363 -0.402 -0.117 0.703 -5.602 -0.397 0.127 
Activities-Specific Balance Confidence Scale           
  AP -6.767 -0.199 0.300 -3.088 -0.329 0.272 -3.881 -0.108 0.691 
 Harmonic Ratio (Head) ML -9.947 -0.281 0.140 -4.230 -0.397 0.180 -4.687 -0.126 0.642 
  VT -12.013 -0.399 0.032* -0.922 -0.127 0.679 -18.297 -0.504 0.047* 
  AP -6.616 -0.171 0.374 -7.332 -0.669 0.012* -7.555 -0.192 0.475 
 Harmonic Ratio (Trunk) ML -6.457 -0.164 0.395 -4.123 -0.424 0.149 -4.191 -0.093 0.731 
  VT -8.144 -0.315 0.096 -0.745 -0.106 0.731 -8.898 -0.319 0.229 
AP = Anteroposterior, ML = Mediolateral, VT = Vertical, * = Significant correlation 
 
